Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2017 2
2018 1
2019 1
2020 2
2021 2
2022 2
2023 4
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.
Ständer S, Pinter A, Hougeir FG, Guyot P, Xu Y, Praestgaard AH, Freemantle N, Rossi AB, Bégo-Le-Bagousse G, Wang Z, Noonan K, Bastian M. Ständer S, et al. Among authors: bego le bagousse g. Dermatol Ther (Heidelb). 2025 Sep;15(9):2537-2551. doi: 10.1007/s13555-025-01479-y. Epub 2025 Jul 11. Dermatol Ther (Heidelb). 2025. PMID: 40646412 Free PMC article.
A Response to "Letter to the Editor Regarding 'Dupilumab Versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison'".
Ständer S, Pinter A, Hougeir FG, Guyot P, Xu Y, Praestgaard AH, Freemantle N, Rossi AB, Bégo-Le-Bagousse G, Wang Z, Noonan K, Bastian M. Ständer S, et al. Among authors: bego le bagousse g. Dermatol Ther (Heidelb). 2026 Feb;16(2):1433-1437. doi: 10.1007/s13555-025-01627-4. Epub 2025 Dec 29. Dermatol Ther (Heidelb). 2026. PMID: 41460564 Free PMC article. No abstract available.
Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use.
Deleuran M, Marcoux D, Bruin-Weller MS, Irvine AD, Baselga E, Ahn K, Castro AP, Bansal A, Chao J, Bégo-Le-Bagousse G, Rossi AB. Deleuran M, et al. Among authors: bego le bagousse g. Acta Derm Venereol. 2021 Jul 15;101(7):adv00504. doi: 10.2340/00015555-3848. Acta Derm Venereol. 2021. PMID: 34043020 Free PMC article. Clinical Trial. No abstract available.
Dupilumab reduces absenteeism in patients with moderate to severe atopic dermatitis: Pooled results from the LIBERTY AD SOLO clinical trials.
de Bruin-Weller M, Simpson EL, Cork M, Chen Z, Msihid J, Taniou C, Eckert L, Gadkari A, Bégo-Le Bagousse G. de Bruin-Weller M, et al. Among authors: bego le bagousse g. J Am Acad Dermatol. 2020 Nov;83(5):1499-1501. doi: 10.1016/j.jaad.2020.05.142. Epub 2020 Jun 3. J Am Acad Dermatol. 2020. PMID: 32504724 Free article. No abstract available.
18 results